Overview: Urine Reducing Substances TestIntroduction: The Urine Reducing Substances Test detects reducing substances in urine to diagnose metabolic disorders, causing diarrhea. Aligned with 2023 AAP guidelines, it uses biochemical methods for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected metabolic disorders.
Other Names: Urine Reducing Substances Assay, Clinitest.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Reducing substances testing began in the 1960s with metabolic disorder research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects reducing substances in urine to diagnose metabolic disorders, guides treatment, and evaluates patients with diarrhea.
Test Parameters: 1. Reducing Substances Presence 2. Type
Pretest Condition: No fasting required. Collect random or 24-hour urine. Report history of diarrhea or metabolic symptoms.
Specimen: Random Urine (sterile container, 5-20 mL), 24-Hour Urine (sterile container, 50-100 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document diarrhea, failure to thrive, or history of metabolic disorders. Include current medications or dietary history.
Consent: Written consent required, detailing the tests purpose, metabolic disorder implications, and risks of sample collection.
Procedural Considerations: Uses chemical assays (e.g., Benedict's test) to detect reducing substances like glucose or galactose in urine. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for metabolic disorder screening.
Factors Affecting Result Accuracy: Improper urine collection or contamination can affect results. Dietary sugars may cause false positives.
Clinical Significance: Positive reducing substances suggest metabolic disorders like galactosemia, guiding dietary or medical therapy. Negative results may require specific sugar testing.
Specialist Consultation: Consult a metabolic specialist or pediatrician for result interpretation and treatment planning.
Additional Supporting Tests: Specific sugar tests, genetic testing, or enzyme assays to confirm metabolic disorder diagnosis.
Test Limitations: Non-specific for metabolic disorder type; clinical correlation is needed. Sample quality affects sensitivity.
References: AAP Metabolic Guidelines, 2023; Journal of Inherited Metabolic Disease, Saudubray JM, 2022.
